Zhejiang Huahai Pharmaceutical (600521.SH): Linagliptin Metformin Tablets () Obtains Drug Registration Certificate.
(600521.SH) announced that the company recently received a notice from the National Medical Products Administration (referred to as "NMPA")...
Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company recently received the "Drug Registration Certificate" for the approval and issuance of linagliptin metformin tablets (II) from the National Medical Products Administration (NMPA).
The approved product is mainly used for type 2 diabetes adult patients who are suitable for treatment with linagliptin and metformin, to improve the blood sugar control level of these patients.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
